The ISCOMATRIX adjuvant has antigen-delivery and -presentation properties, as well as immunomodulatory capabilities that combine to provide enhanced and accelerated immune responses. The responses are broad, including a range of subclasses of antibodies as well as both CD4+ and CD8+ T cells. A range of ISCOMATRIX vaccines (ISCOMATRIX adjuvant combined with antigen) have been evaluated in clinical trials. The results of these completed and ongoing studies indicate that the ISCOMATRIX adjuvant is safe and generally well tolerated and increases the vaccine immune responses.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1586/14760584.6.5.761 | DOI Listing |
Publication Analysis
Top Keywords
iscomatrix adjuvant
16
vaccines iscomatrix
8
immune responses
8
iscomatrix
5
adjuvant prophylactic
4
prophylactic therapeutic
4
therapeutic vaccines
4
adjuvant antigen-delivery
4
antigen-delivery -presentation
4
-presentation properties
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!